Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. monthly Stock Chart
Biogen Inc.
IndexS&P 500 P/E9.76 EPS (ttm)23.33 Insider Own0.10% Shs Outstand196.95M Perf Week0.19%
Market Cap44.84B Forward P/E7.42 EPS next Y30.68 Insider Trans- Shs Float189.98M Perf Month-1.27%
Income4.69B PEG1.62 EPS next Q7.45 Inst Own93.00% Short Float2.01% Perf Quarter-30.98%
Sales13.81B P/S3.25 EPS this Y24.50% Inst Trans-1.85% Short Ratio1.48 Perf Half Y-29.43%
Book/sh70.35 P/B3.24 EPS next Y3.64% ROA18.40% Target Price258.79 Perf Year-25.82%
Cash/sh19.85 P/C11.47 EPS next 5Y6.02% ROE35.30% 52W Range216.12 - 388.67 Perf YTD-24.34%
Dividend- P/FCF7.52 EPS past 5Y22.70% ROI23.60% 52W High-41.42% Beta0.97
Dividend %- Quick Ratio2.60 Sales past 5Y14.20% Gross Margin85.70% 52W Low5.34% ATR4.92
Employees7800 Current Ratio2.80 Sales Q/Q11.50% Oper. Margin42.40% RSI (14)49.74 Volatility1.78% 2.03%
OptionableYes Debt/Eq0.00 EPS Q/Q29.10% Profit Margin33.80% Rel Volume0.56 Prev Close231.26
ShortableYes LT Debt/Eq0.43 EarningsJul 24 BMO Payout0.00% Avg Volume2.59M Price227.67
Recom2.80 SMA20-0.02% SMA50-0.95% SMA200-23.51% Volume1,453,992 Change-1.55%
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Mar-22-19Downgrade Canaccord Genuity Buy → Hold $396 → $275
Mar-21-19Reiterated Guggenheim Neutral $325
Mar-21-19Downgrade William Blair Outperform → Mkt Perform
Mar-21-19Downgrade Wells Fargo Outperform → Market Perform
Mar-21-19Downgrade Mizuho Buy → Neutral
Mar-21-19Downgrade JP Morgan Overweight → Neutral
Mar-21-19Downgrade Goldman Buy → Neutral
Mar-21-19Downgrade Citigroup Buy → Neutral
Mar-21-19Downgrade BofA/Merrill Buy → Neutral
Mar-21-19Downgrade Atlantic Equities Overweight → Neutral
Feb-21-19Downgrade Stifel Buy → Hold $397 → $346
Jun-14-19 12:03PM  Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures Investor's Business Daily
Jun-13-19 05:50PM  Biogen (BIIB) Gains But Lags Market: What You Should Know Zacks
04:12PM  Amgen, Biogen, Gilead and Novo Nordisk have very high capacity for M&A, says Moodys MarketWatch
06:00AM  Ontario grants broader access to SPINRAZA (nusinersen) for patients living with spinal muscular atrophy (SMA) CNW Group
Jun-12-19 12:49PM  Biogen Inc. (NASDAQ:BIIB) Insiders Increased Their Holdings Simply Wall St.
09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
Jun-11-19 07:05PM  Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019 GlobeNewswire
11:26AM  Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder InvestorPlace
Jun-10-19 04:40PM  Is Biogen Inc. (BIIB) A Good Stock To Buy? Insider Monkey
Jun-07-19 05:50PM  Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know Zacks
05:00PM  Celgene's Filing for Ozanimod Accepted for Review in US/EU Zacks
05:41AM  Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million GlobeNewswire
Jun-06-19 04:19PM  Will This Downbeat Biotech Regain Investor Trust With ALS Drugs? Investor's Business Daily
10:38AM  Biogen Stock Is Slipping Because Investors Dont Buy Its News on Lou Gehrigs Disease
May-31-19 09:07AM  Biogen Reports Interim Phase III Data on Diroximel Fumarate Zacks
08:11AM  Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs Zacks
May-30-19 11:02AM  PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts Zacks
07:30AM  New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis GlobeNewswire
07:15AM  The Case for a Biogen Acquisition and 3 Potential Targets
May-29-19 05:50PM  Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
08:59AM  Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma Zacks
May-28-19 07:00AM  Primecaps Golden Lineup: Its Six Funds Come in Pairs Morningstar
May-27-19 11:10AM  Novartis Gene Therapy Crosses The $2 Million Mark Will Others Follow? Investor's Business Daily
06:48AM  Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems Zacks
May-24-19 07:39PM  Novartis $2 million gene therapy for rare disorder is world's most expensive drug Reuters
07:39PM  For Anderson family, an early bet on SMA gene therapy Reuters
01:30PM  Biogen loses edge on blockbuster rare disease market with Novartis' FDA approval American City Business Journals
10:55AM  Biogen Stock One of the Best to Own Next Week Schaeffer's Investment Research
09:31AM  Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound? Zacks
May-23-19 05:27PM  Preclinical biotech Stoke Therapeutics plans $86M IPO American City Business Journals
03:53PM  Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY) Zacks
11:44AM  The Patient View: Biogen Alzheimer's Trial Participant Jeff Borghoff at Healthy Returns CNBC Videos
09:17AM  The Zacks Analyst Blog Highlights: Chubb, Las Vegas Sands, Biogen, Dollar General and Canadian Pacific Zacks
09:06AM  Wedbush Securities Senior Vice President of Equity Research Laura Chico, Ph.D. Initiates Coverage on Six Stocks in the Healthcare and BioTech Space - ACER, ACOR, ALNX, BIIB, DOVA and SAGE PR Newswire
07:10AM  The top-performing hedge funds are buying GE, Facebook, Biogen and these other stocks CNBC
May-22-19 04:30PM  3 Tech Stocks for Growth Investors to Buy Right Now Zacks
02:43PM  Top Research Reports for Chubb, Las Vegas Sands & Biogen Zacks
11:34AM  Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN Zacks
05:35AM  The Best and Worst Big Biotech Stocks, According to One Analyst
May-21-19 04:55PM  We don't yet have the technology to cure Alzheimer's, health-care investor says CNBC
03:00PM  Apple, Biogen, Diamondback Energy and More: Why These Stocks Are Trending Insider Monkey
May-20-19 04:30PM  Biogen Urges Shareholders To Reject Low-Ball Mini-Tender Offer Investor's Business Daily
07:40AM  Biogen urges shareholders to reject 'below-market' mini-tender offer from TRC Capital MarketWatch
07:30AM  Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation GlobeNewswire
May-17-19 05:17PM  Celgene Gets EC Nod for Label Expansion of Revlimid, Imnovid Zacks
May-16-19 02:54PM  Wayfair cracks Fortune 500 list, joins 15 other Mass. companies American City Business Journals
05:00AM  Big Biotech Needs Big M&A to Boost Their Beaten-Down Stocks
May-15-19 07:50AM  Stocks making the biggest moves premarket: Alibaba, Zillow Group, Biogen, McDonald's, Beyond Meat & more CNBC
07:50AM  The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi Benzinga
07:42AM  5 Low Price-to-Book Value Stocks for Great Returns Zacks
May-14-19 08:05PM  NHS England, Biogen reach deal on pricey drug for deadly disorder Reuters
07:07PM  NHS England, Biogen reach deal on pricey drug for deadly disorder Reuters
07:02PM  Biogens SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy GlobeNewswire
03:51PM  Ionis Pharmaceuticals Is 40% of the Way There Motley Fool
May-13-19 04:24PM  Dr. Reddy's (RDY) to Report Q4 Earnings: What's in Store? Zacks
08:00AM  Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease PR Newswire
May-10-19 10:51AM  PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y Zacks
08:40AM  Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer's Disease PR Newswire
May-09-19 12:32PM  Stock Buybacks Surge Kiplinger
May-08-19 04:49PM  Parnassus Endeavor Fund Buys AbbVie, Boosts Biogen
01:44PM  Jeff Auxier Comments on Biogen
01:18PM  Jeff Auxier's 1st Quarter Auxier Focus Fund Shareholder Letter
May-07-19 04:57PM  Biotech ETFs in Focus on String of Q1 Earnings Beats Zacks
04:33PM  This Biotech Has A 'Swing Factor' In SMA Drugs And It's Slugging Biogen Investor's Business Daily
07:30AM  Data at AAN Demonstrate Biogens Leadership and Commitment to Innovation in MS GlobeNewswire
May-06-19 04:53PM  Jerome Dodson Comments on Biogen
11:20AM  Weekly CEO Buys Highlight
07:44AM  Notable Insider Buys This Past Week: ADM, Biogen, Grubhub and More Benzinga
07:30AM  Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen) GlobeNewswire
07:00AM  Biogen Stock Is Near a Multiyear Low. The CEO and a Hedge Fund Bought Millions.
May-05-19 03:27PM  Top Insider Buys Highlight for the Week of May 3
May-02-19 01:21PM  These 6 biotech stocks are promising takeover targets MarketWatch
11:18AM  The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex Zacks
11:05AM  Betting Against Biogen Stock Might Be Fashionable, but Its a Mistake, Analyst Says
10:24AM  What Do Analysts Think About Biogen Inc.'s (NASDAQ:BIIB) Future? Simply Wall St.
08:16AM  The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data Benzinga
May-01-19 04:30PM  Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) GlobeNewswire
01:36PM  David Carlson Buys 2 Stocks, Sells 1 in 1st Quarter
11:52AM  Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates Zacks
09:26AM  What's in the Cards for Sunesis (SNSS) This Earnings Season? Zacks
07:30AM  Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases GlobeNewswire
Apr-30-19 12:46PM  3 Tech Stocks for Growth Investors to Buy Right Now Zacks
11:44AM  Biogen Is 3 Adding Directors. Investors Might Question Whether Thats Bold Enough.
10:54AM  10 Workhorse Health Care Stocks That Never Break a Sweat Kiplinger
10:53AM  The 10 Best Health Care Stocks to Buy for 2019 Kiplinger
07:33AM  Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy GlobeNewswire
Apr-29-19 07:30AM  Biogen Announces Three New Nominees for Election to Board of Directors GlobeNewswire
Apr-28-19 11:19AM  Biogen says it will not give up on Alzheimers after failed trials MarketWatch
Apr-27-19 11:54AM  Cramer's Takeaways for Ford, Chevron, Alibaba, Biogen, Visa
Apr-26-19 04:21PM  Is This Highly-Anticipated Gene Therapy in Trouble? Motley Fool
03:58PM  Alkermes Looks Ahead to Growth Motley Fool
07:26AM  Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1 Zacks
06:10AM  Analysts point to potential Biogen M&A options after Alzheimer's failure American City Business Journals
Apr-25-19 04:37PM  Jerome Dodson's 1st Quarter Parnassus Endeavor Fund Commentary
03:47PM  Biogen Looks to 23 Clinical Programs for Growth Motley Fool
03:10PM  Bitcoin and Biogen among the second round 2019 Stock Draft picks CNBC Videos
02:46PM  Here is who's competing in the 2019 Stock Draft, the rules and the first pick CNBC Videos
12:18PM  IPO Cortexyme Hopes to Succeed in Alzheimer's Where Giants like Biogen Have Failed
10:36AM  Edited Transcript of BIIB earnings conference call or presentation 24-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
10:04AM  AbbVie says Humira rivals from Biogen, Amgen most aggressive so far Reuters
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,12608,525Jun 04 04:56 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,480022,487May 06 04:20 PM
DENNER ALEXANDER JDirectorMay 02Buy231.2438,0008,787,120643,000May 02 05:06 PM
Vounatsos MichelChief Executive OfficerMay 01Buy231.484,3511,007,16921,007May 02 04:30 PM
DENNER ALEXANDER JDirectorMay 01Buy229.4630,0006,883,800605,000May 02 05:06 PM
DENNER ALEXANDER JDirectorApr 30Buy229.2550,34211,540,904575,000May 02 05:06 PM
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM